HYFTOR vs TAGRISSO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. HYFTOR and TAGRISSO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	HYFTOR	TAGRISSO
Rating	New	70/100
Pharmacy pays	~$48.61 /30	—
Type	RX	RX
Active ingredient	SIROLIMUS	OSIMERTINIB MESYLATE
Manufacturer	Nobelpharma	Astrazeneca
Dosage forms	Topical	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms	Non-Small-Cell Lung Carcinoma

hyftor tagrisso

Rating

New

70/100

Pharmacy pays

~$48.61 /30

—

Type

Active ingredient

SIROLIMUS

OSIMERTINIB MESYLATE

Manufacturer

Nobelpharma

Astrazeneca

Dosage forms

Topical

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Hyftor and Tagrisso?

Hyftor contains Sirolimus, while Tagrisso contains Osimertinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.